Global Gastrointestinal Drug Market to 2022 - Pipeline Characterized by Emerging Biologic Therapies, While TNF Inhibitors and PPIs Continue to Dominate Therapy Landscape

ReportsWorldwide has announced the addition of a new report title
Global Gastrointestinal Drug Market to 2022 - Pipeline Characterized by Emerging Biologic Therapies, While TNF Inhibitors and PPIs Continue to Dominate Therapy Landscape to its growing collection of premium market research reports.

Disease and disorders involving the gastrointestinal system are among the most common conditions encountered worldwide, and many of them can have a significant impact on quality of life. The direct and indirect socio-economic burden associated with gastrointestinal disorders is profound. The direct costs of medical consultations and treatments in the US for gastroesophageal reflux disease alone are estimated to amount to $9.3 billion, while the indirect costs due to absenteeism and impairment in work performance total $75 billion (Chait, 2010).

Scope of the Report:

The gastrointestinal market landscape is expected to change substantially with the advent of promising novel pipeline products.

There are 937 gastrointestinal pipeline products in active development, of which small molecules and biologics account for 53% and 38%, respectively.

- Which molecular targets are most prominent within the pipeline?

- How do the key indications differ in terms of molecule type?

- How does the composition of the pipeline compare with that of the existing market?

- What mechanisms of action are most common for pipeline drugs?

Global revenue for the gastrointestinal market is forecast to grow at a CAGR of 4.45%, from $35.7 billion in 2015 to $48.4 billion in 2022.

- Which products will be the biggest drivers for market growth?

- Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the gastrointestinal market set to change?

- What CAGR will these companies register in the forecast period?

To Get Sample Copy of Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=6848

Reasons to buy

This report will allow you to -

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis.

- Visualize the composition of the gastrointestinal market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players.

- Analyze the gastrointestinal pipeline, stratifying it by stage of development, molecule type and molecular target and providing a granular breakdown across key indications.

- Understand the growth in patient epidemiology and market revenue for the gastrointestinal market globally and across the key players and product types.

- Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various gastrointestinal conditions.

- Identify commercial opportunities in the gastrointestinal deals landscape by analyzing trends in licensing and co-development deals.

To view a detailed description and Table of Contents please visit: https://www.reportsworldwide.com/report/global-gastrointestinal-drug-market-to-2022-pipeline-characterized-by-emerging-biologic-therapies-while-tnf-inhibitors-and-ppis-continue-to-dominate-therapy-landscape

About ReportsWorldwide.com

ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.

Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
Phone +1 (617) 398-4994
Fax +1 (617) 398-4995
abigail@reportsworldwide.com

This release was published on openPR.